Time to treatment failure in limited disease small-cell lung cancer patients with poor initial performance status who responded to chemoradiotherapy

被引：0
|
作者：
Manapov, F. [1 ]
Kloecking, S. [2 ]
Niyazi, M. [1 ]
Belka, C. [1 ]
Hildebrandt, G.
Fietkau, R. [3 ]
Klautke, G. [4 ]
机构：
[1] Univ Munich, Munich, Germany
[2] Univ Rostock, Tumorregister, Rostock, Germany
[3] Univ Erlangen Nurnberg, D-91054 Erlangen, Germany
[4] Klinikum Bruderwald, Bamberg, Germany
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2012年 / 188卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：97 / 97
页数：1
相关论文
共 50 条
  • [1] TIME TO TREATMENT FAILURE IN LIMITED DISEASE SMALL-CELL LUNG CANCER PATIENTS WITH POOR INITIAL PERFORMANCE STATUS WHO RESPONDED TO CHEMORADIOTHERAPY
    Manapov, F.
    Kloecking, S.
    Niyazi, M.
    Belka, C.
    Hildebrandt, G.
    Fietkau, R.
    Klautke, G.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S79 - S79
  • [2] CHEMORADIOTHERAPY DURATION CORRELATES WITH OVERALL SURVIVAL IN LIMITED-DISEASE SMALL-CELL LUNG CANCER PATIENTS WITH POOR INITIAL PERFORMANCE STATUS WHO SUCCESSFULLY COMPLETED MULTIMODALITY TREATMENT
    Manapov, F.
    Kloecking, S.
    Niyazi, M.
    Belka, C.
    Hildebrandt, G.
    Fietkau, R.
    Klautke, G.
    LUNG CANCER, 2011, 71 : S35 - S35
  • [3] SUBGROUP ANALYSIS OF OVERALL SURVIVAL ACCORDING TO THE DURATION OF CHEMORADIOTHERAPY IN LIMITED DISEASE SMALL-CELL LUNG CANCER PATIENTS WHO RESPONDED TO MULTIMODALITY TREATMENT
    Manapov, F.
    Kloecking, S.
    Niyazi, M.
    Hildebrandt, G.
    Belka, C.
    Fietkau, R.
    Klautke, G.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S80 - S80
  • [4] Subgroup analysis of overall survival according to the duration of chemoradiotherapy in limited disease small-cell lung cancer patients who responded to multimodality treatment
    Manapov, F.
    Kloecking, S.
    Niyazi, M.
    Belka, C.
    Levitskiy, V
    Hildebrandt, G.
    Fietkau, R.
    Klautke, G.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 : 97 - 97
  • [5] RESPONSE OF PRIMARY THORACIC DISEASE TO CHEMORADIOTHERAPY CORRELATES WITH BRAIN-METASTASIS FREE SURVIVAL IN LIMITED-DISEASE SMALL-CELL LUNG CANCER PATIENTS WITH POOR INITIAL PERFORMANCE STATUS WHO SUCCESSFULLY COMPLETED MULTIMODALITY TREATMENT
    Manapov, F.
    Kloecking, S.
    Niyazi, M.
    Levitskiy, V.
    Belka, C.
    Hildebrandt, G.
    Fietkau, R.
    Klautke, G.
    LUNG CANCER, 2011, 71 : S35 - S35
  • [6] Chemoradiotherapy in limited-disease small-cell lung cancer
    Fukuda, Minoru
    Ogawara, Daiki
    Nakamura, Yoichi
    Kohno, Shigeru
    LUNG CANCER MANAGEMENT, 2012, 1 (02) : 135 - 143
  • [7] Small-Cell Lung Cancer Treatment of Newly Diagnosed Patients with Poor Performance Status
    Aida, Yuka
    Nakazawa, Kensuke
    Shiozawa, Toshihiro
    Ogawa, Ryoko
    Kiwamoto, Takumi
    Morishima, Yuko
    Sakamoto, Toru
    Sekine, Ikuo
    Hizawa, Nobuyuki
    CASE REPORTS IN ONCOLOGY, 2019, 12 (02): : 613 - 620
  • [8] PROGNOSTIC FACTORS IN SET OF LIMITED DISEASE SMALL-CELL LUNG CANCER PATIENTS TREATED WITH CHEMORADIOTHERAPY
    Zemanova, Milada
    Petruzelka, Lubos
    Honova, Hana
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1346 - S1347
  • [9] Topotecan therapy in patients with relapsed small-cell lung cancer and poor performance status
    Lilenbaum, Rogerio C.
    Huber, Rudolf M.
    Treat, Joseph
    Masters, Gregory
    Kaubitzsch, Sabine
    Lane, Stephen
    Wissel, Paul
    CLINICAL LUNG CANCER, 2006, 8 (02) : 130 - 134
  • [10] Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy
    Bernhardt, Denise
    Aufderstrasse, Sophie
    Koenig, Laila
    Adeberg, Sebastian
    Bozorgmehr, Farastuk
    Christopoulos, Petros
    El Shafie, Rami A.
    Hoerner-Rieber, Juliane
    Kappes, Jutta
    Thomas, Michael
    Herth, Felix
    Steins, Martin
    Debus, Juergen
    Rieken, Stefan
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 6563 - 6569
12345